Hadassah University Hospital and Hadasit, the technology transfer company of Hadassah Medical Organization, announced today that Hadassah scientists had reduced symptoms of multiple sclerosis in animals using embryonic stem cells.
The scientists demonstrated for the first time that transplanted neural cells derived from human embryonic stem cells can reduce the clinical symptoms in animals with a form of multiple sclerosis.
The findings of the study are published in on-line medical journal PLoS One in an article titled “Neuroprotective effect of transplanted human embryonic stem cell-derived neural precursors in an animal model of multiple sclerosis”.
“Human embryonic stem cell-derived neural precursors were transplanted into the brains of mice with an experimental form of MS. The grafted human cells integrated in the mice brains and migrated towards the sites of inflammation. They suppressed the inflammatory process in the brain, and consequently protected the animals from demyelination and nerve cell extension (axonal) injury, which are the pathological hallmarks of MS,” said Professor Benjamin Reubinoff.
Multiple sclerosis, the most common cause of neurological disabilities in young adults, is caused by an inflammatory reaction of the patient’s own immune system against the myelin sheath that envelops the nerve processes. The destruction of myelin leads to the degeneration and loss of nerve cells and permanent neurological disabilities. MS affects 2.5 million people worldwide.
Cell Cure Neurosciences, a Hadasit BioHoldings Ltd (TASE: HDST) company focused on the development of cells derived from human embryonic stem cells for the treatment of neurodegenerative diseases, has started a translational research program that will lead to clinical trials in MS patients.
Cell Cure Neurosciences CEO Charles Irving, PhD, will be making a presentation on stem cell research in Israel at the upcoming 2008 World Stem Cell Summit in Madison, Wisconsin on September 22nd.
Published by Globes [online], Israel business news - www.globes-online.com - on September 8, 2008
© Copyright of Globes Publisher Itonut (1983) Ltd. 2008 Transplanted neural cells derived from human embryonic stem cells reduced the clinical symptoms in animals with a form of multiple sclerosis. Globes' correspondent Hadassah University Hospital and Hadasit, the technology transfer company of Hadassah Medical Organization, announced today that Hadassah scientists had reduced symptoms of multiple sclerosis in animals using embryonic stem cells.
The scientists demonstrated for the first time that transplanted neural cells derived from human embryonic stem cells can reduce the clinical symptoms in animals with a form of multiple sclerosis.
The findings of the study are published in on-line medical journal PLoS One in an article titled “Neuroprotective effect of transplanted human embryonic stem cell-derived neural precursors in an animal model of multiple sclerosis”.
“Human embryonic stem cell-derived neural precursors were transplanted into the brains of mice with an experimental form of MS. The grafted human cells integrated in the mice brains and migrated towards the sites of inflammation. They suppressed the inflammatory process in the brain, and consequently protected the animals from demyelination and nerve cell extension (axonal) injury, which are the pathological hallmarks of MS,” said Professor Benjamin Reubinoff.
Multiple sclerosis, the most common cause of neurological disabilities in young adults, is caused by an inflammatory reaction of the patient’s own immune system against the myelin sheath that envelops the nerve processes. The destruction of myelin leads to the degeneration and loss of nerve cells and permanent neurological disabilities. MS affects 2.5 million people worldwide.
Cell Cure Neurosciences, a Hadasit BioHoldings Ltd (TASE: HDST) company focused on the development of cells derived from human embryonic stem cells for the treatment of neurodegenerative diseases, has started a translational research program that will lead to clinical trials in MS patients.
Cell Cure Neurosciences CEO Charles Irving, PhD, will be making a presentation on stem cell research in Israel at the upcoming 2008 World Stem Cell Summit in Madison, Wisconsin on September 22nd.
Published by Globes [online], Israel business news - www.globes-online.com - on September 8, 2008
© Copyright of Globes Publisher Itonut (1983) Ltd. 2008